Skip to content

Study on the dynamic regulation mechanism of brain networks in rTMS intervention for chronic insomnia

Study on the dynamic regulation mechanism of brain networks in rTMS intervention for chronic insomnia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087749
Enrollment
Unknown
Registered
2024-08-02
Start date
2021-06-21
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic insomnia

Interventions

RDPFC real group:The stimulation target was placed in the dorsolateral region of the right prefrontal lobe, 1x daily for 25min, 110% RMT, 1360 pulses, totally 4 weeks
R_PCC real group:The stimulation target is placed in the right posterior parietal lobe, 1x daily for 25min, 110% RMT, 1360 pulses, totally 4 weeks
Sham group:The stimulation target was placed in the dorsolateral region of the right prefrontal lobe or he right posterior parietal lobe
1x daily for 25min, 110% RMT, 1360 pulses, totally 4 weeks

Sponsors

Shenzhen People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. gender-neutral 2. right-handed 3. 30-50 years of age 30 50 years old; 4. meets the diagnostic criteria for insomnia in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5); 5. sleep disturbance occurs at least 3 nights per week and lasts for at least 3 months; 6. PSQI =7; 7. HAMD <20 and HAMA <21; 8. not currently taking insomnia-related medication and able to accept not taking insomnia medication during the period of enrolment; 9. able to complete the 1-month follow-up visit.

Exclusion criteria

Exclusion criteria: 1. concurrent comorbidity with depression, bipolar disorder, epilepsy, chronic pain, sleep apnea syndrome, restless legs syndrome and other diseases that may cause insomnia; 2. severe liver, kidney, cardiovascular, cerebrovascular, haematopoietic system diseases and their serious complications; 3. pregnant or breastfeeding women; 4. long term alcohol or drug abuse; 5. any contraindications to rTMS (including metal implanted in the body and devices such as pacemakers); 6. previous rTMS treatment within 1 year; 7. severe cognitive impairment, language impairment or inability to co-operate with treatment, MMSE <26 points.

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Index, PSQI;Insomnia Severity Index scores;MMSE scores;

Secondary

MeasureTime frame
Hamilton Depression Scale scores;Hamilton Anxiety Scale scores;Resting-state EEG features;TMS-EEG;

Countries

China

Contacts

Public ContactGuo Yi

Shenzhen People's Hospital

774654959@qq.com+86 185 2059 6397

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026